Okklo Life Sciences

Company
Technology
Programs
Partnering
News
Contact
- Where to meet us
- Disclaimer

Via our unique expertise and network we can design novel cyclodextrins for a wide variety of therapeutic areas

Our vision is to be the leading biotech providing cyclodextrin-based therapeutics to improve the life of patients.

Okklo Life Sciences: custom design and development of therapeutic cyclodextrins

Okklo Life Sciences

Novel therapeutic solutions using cyclodextrin-based technologies

Drug Discovery Today

All eyes on Lab Innovations 2021 07/18/2021
The Current issue of “The view from here” is concerned with Cardiovascular Drugs 07/08/2021
Digital brain biomarker company Monument Therapeutics raises £2.6 million 07/07/2021
Moderna and Samsung Biologics Announce Agreement for Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine 05/25/2021
Lilly and MiNA Therapeutics Announce saRNA Research Collaboration 05/13/2021

Follow us on:

Recent Okklo News

Okklo’s hematology asset will be further developed by Alveron Pharma 05/16/2019
Okklo and SolAeroMed partner to develop cyclodextrins for cystic fibrosis treatment 06/27/2017
Okklo Life Sciences B.V. and Sanquin sign commercialization agreement to enter IND enabling studies and clinical development. 01/10/2017
Okklo receives RedMedTech Ventures funding and extends collaboration with Sanquin 05/15/2016

Company
Technology
Programs
Partnering
News
Contact

Copyright © 2016 | Okklo Life Sciences | All Rights Reserved